13D Filing on AYTU (As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 7,695,064 Shares, constituting 40.0% of the Shares, based upon 19,235,395 Shares outstanding as of the date hereof.)
13D Filing on INNV (As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 300,000 Shares, constituting 11.5% of the Shares, based upon 2,604,476 Shares outstanding as of the date hereof.)
RELATED: Adding Innovus Pharma (INNV) $2.50 to Watch List.
Currently, the Company has one well-known institutional investor (from most recent SEC filing) which is Armistice Capital.
Armistice was the winner of 2017 US Hedge Fund Performance Awards by HFM for long/short equity, long/short equity long-term performance (5 years) under $1bn, and single manager long-term performance under $1bn. Armistice is led by enigmatic Steven Boyd who was ranked #2 in the Institutional Analyst magazines 2018 “Rising Hedge Fund Stars.”
VOTING AND SUPPORT AGREEMENT
THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of September 10, 2019, by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), Aytu Bioscience Inc., a Delaware corporation (“Aytu”), Aytu Acquisition Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Aytu (“Merger Sub”) and the stockholder of Aytu listed on Schedule A hereto (“Securityholder”). Capitalized terms used but not defined herein are used as they are defined in the Merger Agreement (as defined below).
